PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer

Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we sought to dissect the mechanisms underlying PARP inhibitor-induced changes in the tumor microenvironment of BRCA1-deficient...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Discov
Asıl Yazarlar: Pantelidou, Constantia, Sonzogni, Olmo, De Oliveria Taveira, Mateus, Mehta, Anita K., Kothari, Aditi, Wang, Dan, Visal, Tanvi, Li, Michelle K., Pinto, Jocelin, Castrillon, Jessica A., Cheney, Emily M., Bouwman, Peter, Jonkers, Jos, Rottenberg, Sven, Guerriero, Jennifer L., Wulf, Gerburg M., Shapiro, Geoffrey I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6548644/
https://ncbi.nlm.nih.gov/pubmed/31015319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-1218
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller